Response to PARPi has initially been observed in ovarian cancer patients with alterations in the genes BRCA1 and BRCA2,17, 18 but later studies reported that clinical response was also observed in patients with BRCA1/2 wildtype status.19, 20. Here, BRCA1 is linked to ovarian carcinoma.